The Cantor Fitzgerald Analysts Give Paratek Pharmaceuticals Inc. (PRTK) a $28.00 Price Target

The Cantor Fitzgerald Analysts Give Paratek Pharmaceuticals Inc. (PRTK) a $28.00 Price Target

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) has been assigned a $28.00 price target by analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 110.53% from the stock’s previous close.

Several other brokerages have also weighed in on PRTK. Zacks Investment Research lowered shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 6th. HC Wainwright reiterated a “buy” rating on shares of Paratek Pharmaceuticals in a report on Tuesday, August 16th. Guggenheim reiterated a “buy” rating on shares of Paratek Pharmaceuticals in a report on Tuesday, August 16th. Finally, Leerink Swann reiterated an “outperform” rating and set a $23.00 price objective on shares of Paratek Pharmaceuticals in a report on Thursday, October 27th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $33.57.

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) traded up 1.14% on Wednesday, reaching $13.30. 39,910 shares of the company were exchanged. The stock’s market capitalization is $300.95 billion. The company has a 50-day moving average price of $12.31 and a 200 day moving average price of $13.45. Paratek Pharmaceuticals has a 1-year low of $9.80 and a 1-year high of $22.00.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings data on Wednesday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.38) by $0.34.

Hedge funds have recently modified their holdings of the stock. Omega Fund Management LLC increased its stake in shares of Paratek Pharmaceuticals by 21.6% in the second quarter. Omega Fund Management LLC now owns 2,600,410 shares of the specialty pharmaceutical company’s stock valued at $36,172,000 after buying an additional 461,538 shares during the period. Stoneridge Investment Partners LLC purchased a new stake in shares of Paratek Pharmaceuticals during the second quarter valued at about $329,000. Schwab Charles Investment Management Inc. increased its stake in shares of Paratek Pharmaceuticals by 44.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 25,108 shares of the specialty pharmaceutical company’s stock valued at $350,000 after buying an additional 7,700 shares during the period. Turner Investments L.P. purchased a new stake in shares of Paratek Pharmaceuticals during the second quarter valued at about $883,000. Finally, General American Investors Co. Inc. increased its stake in shares of Paratek Pharmaceuticals by 72.2% in the second quarter. General American Investors Co. Inc. now owns 477,076 shares of the specialty pharmaceutical company’s stock valued at $6,636,000 after buying an additional 200,000 shares during the period. 79.44% of the stock is owned by institutional investors.

Paratek Pharmaceuticals Company Profile

Related posts

Leave a Comment